Stock Scorecard
Stock Summary for Immunocore Holdings plc (IMCR) - $58.00 as of 4/26/2024 3:21:56 PM EST
Total Score
5 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IMCR
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IMCR
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IMCR
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for IMCR
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for IMCR
Financial Details for IMCR
Company Overview |
|
---|---|
Ticker | IMCR |
Company Name | Immunocore Holdings plc |
Country | USA |
Description | Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/31/2024 |
Stock Price History |
|
Last Day Price | 58.00 |
Last Day Price Updated | 4/26/2024 3:21:56 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 407,127 |
52-Week High | 76.98 |
52-Week Low | 42.21 |
Last Price to 52 Week Low | 37.41% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 64.46 |
Sector PE | 56.64 |
5-Year Average PE | -0.78 |
Free Cash Flow Ratio | 6.55 |
Industry Free Cash Flow Ratio | 20.47 |
Sector Free Cash Flow Ratio | 30.65 |
Current Ratio Most Recent Quarter | 3.80 |
Total Cash Per Share | 8.85 |
Book Value Per Share Most Recent Quarter | 7.42 |
Price to Book Ratio | 6.09 |
Industry Price to Book Ratio | 7.85 |
Sector Price to Book Ratio | 22.15 |
Price to Sales Ratio Twelve Trailing Months | 11.29 |
Industry Price to Sales Ratio Twelve Trailing Months | 9.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.17 |
Share Statistics |
|
Total Shares Outstanding | 50,006,000 |
Market Capitalization | 2,900,348,000 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | -67.70% |
Annual Earnings Growth | -34.11% |
Reported EPS 12 Trailing Months | -1.41 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -31.77 |
Net Income Twelve Trailing Months | -55,287,000 |
Net Income Past Year | -55,287,000 |
Net Income Prior Year | -41,224,000 |
Quarterly Revenue Growth YOY | 12.20% |
5-Year Revenue Growth | 60.18% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 442,626,000 |
Total Cash Past Year | 442,626,000 |
Total Cash Prior Year | 332,539,000 |
Net Cash Position Most Recent Quarter | 294,615,000 |
Net Cash Position Past Year | 294,615,000 |
Long Term Debt Past Year | 148,011,000 |
Long Term Debt Prior Year | 39,500,000 |
Total Debt Most Recent Quarter | 148,011,000 |
Equity to Debt Ratio Past Year | 0.71 |
Equity to Debt Ratio Most Recent Quarter | 0.71 |
Total Stockholder Equity Past Year | 368,843,000 |
Total Stockholder Equity Prior Year | 338,903,000 |
Total Stockholder Equity Most Recent Quarter | 368,843,000 |
Options |
|
Put/Call Ratio | 0.43 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -2.01 |
MACD Signal | -2.17 |
20-Day Bollinger Lower Band | 55.26 |
20-Day Bollinger Middle Band | 65.82 |
20-Day Bollinger Upper Band | 76.39 |
Beta | 0.89 |
RSI | 46.58 |
50-Day SMA | 59.80 |
200-Day SMA | 0.00 |
System |
|
Modified | 4/27/2024 3:14:33 AM EST |